HIRUDINE MUTANT, PRODUCTION THEREOF, ANTICOAGULANT, SECRETORY VECTOR, MICROORGANISM TRANSFORMED BY SAID VECTOR, AND PRODUCTION OF PRODUCT FROM SAID MICROORGANISM

Abstract: A hirudine mutant HVIC3 prepared by replacing an amino acid sequence starting with the 53rd amino acid residue of hirudine HV1 by an amino acid sequence starting with the 53rd amino acid residue of hirudine HV3, said mutant not only having a high antithrombin effect, but also serving to inhibit the elongation of bleeding time. Escherichia coli transformed by a foreign protein secretory vector comprising a DNA sequence containing an origin (ori) of pUC plasmid, a DNA sequence of tac promoter or trp promoter, a DNA sequence coding for signal peptide and a DNA sequence coding for foreign protein, which secretes and produces foreign proteins in large amounts outside the cells.

Description: Technical Field The present invention relates to a new hirudin analog, a DNA sequence encoding this hirudin analog, a method of manufacturing this hirudin analog using said DNA sequence, and an anti-coagulant pharmaceutical composition. The new hirudin analog described in the present invention is useful as an anti-coagulant by virtue of its higher anti-thrombin activity and lower tendency to cause bleeding compared with known hirudin HV1. Background Art Hirudin is an anti-coagulation factor secreted from the salivary glands of medicinal leeches, Hirudo medicinalis , and is a mixture of peptides consisting of 65 and 66 amino acids. The structure of hirudin was determined by Dodt et al. [FEBS Lett. 165 , 180(1984)] as hirudin variant 1 (HV1). Another variant, hirudin HV2, [Harvey et al., Proc.Natl.Acad. Sci. USA, 83 , 1084(1986)] has nine different amino acids in comparison with hirudin HV1, and still another variant, hirudin HV3, [Dodt et al., Biol. Chem. Hoppe-Seyler, 367 , 803(1986)] has ten different amino acids in comparison with HV2, having the same sequence as HV2 up to Ser 32 , and inserting an amino acid (Ala 63 ) in the C-terminal region. The structures of these three hirudin variants are shown in Fig. 1. These natural type variants comprise 65 or 66 amino acids, and two domains are discernible. These are the spherical structured N-terminal region with three disulfide bonds, and the acidic C-terminal region exhibiting homology with the thrombin cleaving region of the pro-thrombin molecule, or with the fibrinogen cleaving region. The present inventors have discovered that HV1 contains Leu 64 -Gln 65 , while HV3 contains Asp 65 -Glu 66 in the C-terminal amino acid region. A patent application has been filed (Japanese Laid Open Patent Publication 3-164184 (1991)) on the synthesis of synthetic genes for HV1 and HV3 and their expression in E . coli . Hirudin variants HV1, HV2 and HV3, having anti-thrombotic activity, are not acceptable drugs for clinical use because of their serious side effects, such as prolongation of bleeding time. Several systems for producing hirudin by genetic engineering technology have been proposed; however, a satisfactory method has not yet been developed. From an industrial point of view, an extracellular production system is particularly desirable, since if the produced protein can be secreted extracellularly, there will be advantages not only simplifying the separation and purification of the product because of its presence in active form, but also because the product will be protected from digestion by intracellular bacterial proteases. Methods using Bacillus subtilis , yeast or E. coli as hosts have been proposed for the production of hirudin by secretion. Methods using Bacillus subtilis as host are disadvantageous in that plasmids are generally unstable in this bacterium, resulting in frequent curing of plasmids, making the stable protein production difficult, or the protein products in the medium are likely to be digested by its own proteases also secreted into the medium. Methods proposed for hirudin production (for example Japanese Laid Open Patent Publication 2-35084 (1990)) have not solved such problems, and the production yield is only about 100 mg / L. In methods using yeast as hosts, it is known that the C-terminal amino acids of the products are hydrolyzed by carboxypeptidase. In a prior report (N. Riehl-Bellon et al., Biochemistry 1989, 28 , 2941-2949), by-products having 1 or 2 amino acid residues hydrolyzed off from the C-terminal end of HV2 are disclosed. To overcome this problem, a method using carboxypeptidase-deficient yeasts (Japanese Laid Open Patent Publication 2-104279 (1990)) as hosts has been proposed, but has not led to sufficient productivity. Using E . coli as host, a method using the alkaline phosphatase signal sequence has been reported (J. Dodt et al., FEBS Lett. 202 , 373-377 (1986)). Although this is a secretion system, the product is secreted mainly into the periplasmic space, and is not satisfactory since it requires the disruption of bacterial cells by an additional recovery process step such as osmotic shock, and the product yield is as low as 4 mg / 1. Disclosure of Invention The present inventors have produced various hirudin analogs based on the primary structure of the aforesaid hirudin HV1, HV2 and HV3 to compare their properties in animal models. They discovered out that a hirudin analog (chimeric hirudin) having the hirudin HV1 amino acid sequence up to the 52nd amino acid and thereafter substituted with the sequence of HV3 exhibited not only high anti-thrombin activity, but also shortening of the prolongation of bleeding time. Moreover, the present inventors have actively studied the extracellular production of foreign proteins in high yield using E . coli as host, and completed the present invention by discovering that when a replication origin (ori) of a pUC plasmid is used as a replication origin in a secretion vector with the DNA sequence for a signal peptide and a promoter, foreign protein can be secreted from E . coli in large quantity. Therefore, the present invention relates to a new hirudin analog having high anti-thrombin activity. Also, the present invention relates to a DNA sequence encoding the amino acid sequence of the hirudin analog having the aforesaid high anti-thrombin activity and low bleeding tendency, transformed microorganisms produced by transforming E . coli with expression vectors including said DNA sequence, and a method for manufacturing hirudin analogs by expressing said DNA sequence using the aforesaid transformed microorganisms, and recovering said hirudin analog. The present invention also relates to an anti-coagulant drug having the aforesaid hirudin analog as an active ingredient. The new hirudin analog HV1C3 of the present invention has the amino acid sequence shown in the following primary structure: An exemplary DNA sequence encoding the amino acid sequence of this analog can be shown by the following formula: The hirudin analog of the present invention shown in Formula -1 can be synthesized by chemical synthesis, or it can be produced by genetic engineering methodology. To manufacture the hirudin analog by genetic engineering, first, as described in a later example, the hirudin HV1 secreting plasmids pMTSHV1 and pMKSHV1 were constructed and used to transform E . coli . Hirudin HV1 was produced by secretion using the transformed microorganisms. Plasmid pMTSHV1 comprises a promoter (Ptrp), a DNA sequence encoding a signal peptide (PhoA signal), a DNA sequence encoding the amino acid sequence of hirudin HV1, a replication origin (ori) and a DNA sequence including a translation termination signal (rrnBT 1 T 2 ), as shown in Fig. 3. In the present invention, in order to substitute after the 52nd amino acid of hirudin HV1 with the amino acid sequence of HV3, the HV1 secreting plasmid pMTSHV1 was cleaved with a restriction enzyme to remove the DNA sequence encoding the amino acid sequence after the 52nd amino acid of hirudin HV1. On the other hand, the DNA sequence encoding the amino acid sequence beginning with the 53rd amino acid of the HV3 expression plasmid pUCHV3 was excised using a restriction enzyme. The DNA having the sequence encoding up to the 52nd amino acid of hirudin HV1 from plasmid pMTSHV1 and the DNA encoding the amino acid sequence beginning with the 53rd amino acid of hirudin HV3 derived from plasmid pUCHV3 were ligated with DNA ligase to construct the plasmid pMTSHV1C3 containing the DNA encoding the amino acid sequence of the hirudin analog of the present invention. Plasmid pMTSHV1C3 comprises a DNA sequence including a promoter, signal peptide and replication origin (ori) derived from plasmid pMTSHV1, a DNA sequence encoding the 1st - 52nd amino acids of hirudin HV1 and a translation termination signal, and a DNA sequence encoding the amino acids beginning with the 53rd amino acid of hirudin HV3 derived from plasmid pUCHV3, which is inserted between the aforesaid DNA sequence coding the 1st - 52nd amino acids of hirudin HV1 and the translation termination signal. The hirudin analog of the present invention is produced intracellularly and is secreted into the medium when plasmid pMTSHV1C3 is introduced into E . coli , followed by cultivation of the transformed microorganisms. In the present invention, the hirudin analog was separated by generally known methods, and purified by methods such as column chromatography, reverse-phase HPLC, etc. The obtained hirudin analog exhibited higher anti-thrombin activity and lower bleeding tendency compared with hirudin HV1 in the animal model. It can be formulated into an excellent anti-coagulant drug by preparing it by generally known methods of formulation. In other words, the hirudin analog of the present invention can be further prepared by any common methods using any common carriers for pharmaceutical use or additives for formulation. The pharmaceutical composition administered intravenously, intracutaneously, subcutaneously or intramuscularly, or non-orally topically. Although the proper dose will be determined for each case by considering factors such as the symptoms, age and sex of patient, it is generally in the range of 0.1 mg to 100 mg for an adult per day, and the total amount will be administered in one to several doses. Brief Description of the Drawings Fig. 1 shows the amino acid sequence of hirudins HV1, HV2, HV3, and HV1C3. Fig. 2 shows the DNA sequence of the phoA signal peptide. Fig. 3 shows an outline of the construction of hirudin HV1 secreting plasmid pMTSHV1. Fig. 4 shows an outline of the construction of plasmid pMKSHV1. Fig. 5 shows an outline of the construction of hirudin HV1C3 secreting plasmid pMTSHV1C3. Fig. 6 (A) shows the C4 reverse phase HPLC profile of hirudin HV1; (B) shows the C4 reverse phase HPLC profile of hirudin HV1C3, respectively. Fig. 7 shows the DNA sequence of the tac promoter Fig. 8 shows the DNA sequence of the trp promoter Best Mode for Carrying Out the Invention The procedures for constructing plasmids pUCHV1, pMT1 and pMK2 for use in constructing pMTSHV1 or pMKSHV1 as hirudin HV1 secretion plasmids used in the present invention, and of plasmid pUCHV3 for use in constructing plasmid pMTSHV1C3, are provided in the following reference examples. [Reference example 1] Preparation of plasmid pUCHV1 and plasmid pUCHV3 10 µg of commercially available plasmid pUC18 was digested with 30 units of EcoRI and 30 units of HindIII at 37°C for 2 hours. The vector moiety was then separated by agarose gel electrophoresis followed by extraction. Proteins were removed by phenol extraction; DNA was precipitated with cold ethanol and dissolved in 50µl of TE buffer solution (10mM Tris-HCl. pH8.0, 1mM EDTA). To this amount of solution which should contain 50 ng of DNA, 10 µl of 66mM Tris-HCl, pH7.5, 5mM MgCl 2 , 5mM DTT, 1mM ATP, and 300 units of T4 DNA ligase containing double stranded HV1 or HV3 DNA was added, followed by reaction overnight at 16°C to generate plasmid pUCHV1 or pUCHV3, in which the HV1 gene or HV3 gene was inserted, respectively, between the EcoRI and HindIII sites of plasmid pUC18. [Reference example 2] Preparation of plasmid pMK2 and plasmid pMT1 (a) Preparation of plasmid pMK2 A fragment containing the tac promoter which was obtained by cleaving commercially available plasmid pKK223-3 (Pharmacia) with the restriction enzymes PvuI and NruI, a fragment containing a replication origin (ori) obtained by cleaving commercially available pUC18 with restriction enzymes PvuI and PvuII, and a fragment containing the ampicillin resistance gene were ligated using T4 DNA ligase. The thus obtained fragment was introduced into E . coli JM109, followed by culturing, screening for ampicillin resistance, and a vector having both the tac promoter and the replication origin (ori) of pUC18 was obtained, and designated as pMK2. (b) Preparation of plasmid pMT1 10 µg of plasmid pMK2 was digested with 30 units of EcoRI and Eco47III, removing the fragment containing the tac promoter, and then the fragment containing the replication origin (ori) was recovered by agarose gel electrophoresis. The DNA fragment containing the tip promoter was synthesized by a DNA synthesizer. This fragment was ligated with the aforesaid fragment generated by digesting pMK2 with EcoRI and Eco47III, using T4 DNA ligase at 16°C overnight. The ligation products were used to transform E . coli JM109 to prepare a vector having both the tip promoter and the replication origin (ori) of plasmid pMK2. The DNA sequence of this plasmid was confirmed by the method of Sanger et al., and designated as pMT1. The present invention is shown in detail hereinafter via the following [Reference Example 3] (1) Construction of hirudin HV1 secretion plasmid pMTSHV1 Plasmid pMTSHV1 was constructed according to the procedure shown in Fig. 3. Four oligonucleotides indicated in Fig. 2 were synthesized to construct a DNA fragment corresponding to the signal peptide of alkaline phosphatase (phoA) of E . coli and the DNA fragment encoding Val 1 -Val 2 of the N-terminal amino acid of hirudin HV1. After deprotection, each oligonucleotide was purified by 10% polyacrylamide gel electrophoresis. After 500 pmol of each of the two oligonucleotides S2 and S4 were phosphorylated, 20 pmol each of the 4 oligonucleotides were mixed, annealed and then treated at 16°C overnight in 20 µl solution containing T4 DNA ligase. After removal of protein using phenol and chloroform, and precipitation by cold ethanol, the desired double stranded DNA fragment was obtained. 1/10 the amount of the obtained fragment and 100 ng of plasmid pUCHV1 (Japanese Laid Open Patent Publication 3-164184 (1991)) cleaved with restriction enzymes EcoRI and AccI were reacted with T4 DNA ligase at 16°C overnight. Hybrid plasmid pSHV1, containing the fusion gene in which the DNA sequence encoding hirudin HV1 is ligated immediately after the sequence encoding the phoA signal peptide, was obtained by transforming E . coli JM109. The DNA sequence of this plasmid pSHV1 was confirmed by the method of Sanger et al. 10 µg of pSHV1 was digested with restriction enzymes EcoRI (30 units) and HindIII (30 units), and the 276bp fused gene fragment was purified by agarose gel electrophoresis. 100 ng of the obtained DNA fragment and 100 ng of DNA prepared by digesting E . coli expression vector pMT1 (Japanese Laid Open Patent Publication 3-76579 (1991)) with restriction enzymes EcoRI and HindIII, followed by purifying the DNA fragments by agarose gel electrophoresis, were ligated using T4 DNA ligase at 16°C overnight. The resulting reaction mixture was used to transform E . coli JM109 to obtain the hirudin HV1 secretion plasmid pMTSHV1, in which the fused gene encoding the phoA signal peptide and hirudin HV1 is follows trp promoter region. The DNA sequence of pMTSHV1 was confirmed by the method of Sanger et al. (2) Construction of the hirudin HV1 secreting plasmid pMKSHV1 Plasmid pMKSHV1 was constructed according to the method shown in Fig. 4. The aforesaid fused DNA encoding the phoA signal peptide and hirudin HV1, and the DNA fragment obtained by digesting E . coli expression plasmid pMK2 (Japanese Laid Open Patent Publication 3-76579 (1991)) with restriction enzymes EcoRI and HindIII, were ligated using T4 DNA ligase; the ligation products were used to transform E . coli JM109, and the hirudin HV1 secreting plasmid pMKSHV1 having the fused gene inserted downstream of the tac promoter was obtained. The DNA sequence of plasmid pMKSHV1 was confirmed by the method of Sanger et al. [Example 1] (1) Preparation of chimeric hirudin HV1C3 secretion plasmid pMTSHV1C3 Plasmid pMTSHV1C3 was constructed according to the procedure described in Fig. 5. To substitute after the 52nd amino acid of hirudin HV1 with the sequence of HV3, the HV1 secretion plasmid pMTSHV1 (10µg) was digested with restriction enzymes Kpn I (30 units) and Hind III (30 units), followed by agarose gel electrophoresis to purify a DNA fragment of 2.8 Kbp. Similarly, 10 µg of plasmid pUCHV3 (Japanese Laid Open Patent Publication 3-164184 (1991)) was also digested with Kpn I and Hind III, and an 80 bp DNA fragment encoding the C-terminal amino acid sequence of HV3 was purified. 100 ng of both DNA fragments were reacted with T4 DNA ligase at 16°C overnight, and the resulting reaction mixture was used to transform E . coli JM109 to obtain chimeric hirudin HV1C3 secretion plasmid pMTSHV1C3. The DNA sequence of plasmid pMTSHV1C3 was confirmed by the method of Sanger et al. (2) Production of chimeric hirudin HV1C3 by secretion using hirudin secretion plasmid pMTSHV1C3 E . coli RR1 (FERM BP-3130) transformed with plasmid pMTSHV1C3 which was constructed in (1) above was cultured in 2 x YT medium containing 100 µg/ml of ampicillin. After culturing at 37°C for 24 hours, 1ml of culture medium was collected, and osmotic shock was applied in order to measure the anti-thrombin activity of the periplasmic fraction. As a result, 3060 ATU of anti-thrombin activity per 1ml of culture medium was detected. (3) Secretion of chimeric hirudin HV1C3 into the fermentation or culture medium by transformed strain E. coli JM109/pMTSH1C3 When E . coli JM109 (FERM BP-3104) transformed with plasmid pMTSHV1C3 was cultured in 2 L of 2 x YT culture medium containing 2% glucose in a 5L fermenter with agitation and aeration at 37°C for 24 hours, a total anti-thrombin activity of 6050 ATU/ml, 350ATU/ml in the periplasm, and 5700ATU/ml in the culture medium, was detected. (4) Purification of chimeric hirudin HV1C3 Hirudin HV1C3 was purified from the culture medium obtained in (3) above as follows After fermentation, 1.5 L of culture medium were collected and centrifuged at 6,000 x g for 10 minutes to separate supernatant from cellular debris. Since the salt concentration of the supernatant was 1.3% when it was measured with a salt meter, the supernatant was diluted 4-fold with 10mM potassium phosphate buffer (pH7.0) and filtered through a 3.2µm filter (Pole Co. Ltd). The filtrate was loaded on a QAE-toyopearl column (4.4 x 7cm) equilibrated with 10mM potassium phosphate buffer (pH7.0). After loading the sample, the column was equilibrated in buffer, followed by stepwise elution of hirudin HV1C3 with 0.2M NaCl. The eluted solution was concentrated using an Amicon Diaflow membrane (YM5), followed by gel filtration on Sephacryl S-100HR pre-equilibrated with 10mM potassium phosphate buffer (pH7.0) for desalting. The active fractions were loaded on a column of DEAE-toyopearl (4.4 x 40 cm) equilibrated with 10mM potassium phosphate buffer (pH7.0), washed thoroughly, and then eluted with a linear gradient created between 3 L of the equilibration buffer and 3 L of 0.3M NaCl in equilibration buffer. Final purification was carried out on a C4 reverse phase HPLC column with Delta-prep 3000, which is a Waters' product. The purified hirudin HV1C3 was obtained by eluting it from the column using a linear gradient of 15 to 30% (v/v) acetonitrile containing 0.065% (v/v) trifluoro-acetate. When the amino acid sequence of purified chimeric hirudin HV1C3 was determined, the C-terminal amino acid sequence was confirmed to be different from HV1, as designed, as shown in Fig. 1. The specific activity was 11,250 ATU/mg. The HPLC profiles of purified HV1 and HV1C3 are shown in Fig. 6. The experiment was carried out with a VYDAC C4 (0.46 x 25cm) column using a linear gradient of acetonitrile from 15 to 30% at a flow rate of 1 ml/min for 30 minutes. [Example 2] Inhibitory action of hirudin against thrombin induced death Thrombin (10 NIH unit / 10g) was administered intravenously to male mice (20 - 25g), without anesthesia, and the anti-thrombin activity of the tested compound was evaluated by observing the disappearance of roll over reflection and `oath as indexes. All the tested compounds were dissolved in saline, and 0.05 ml/10g were administered intravenously 5 min prior to the thrombin injection. The results are shown in Table 1. Inhibitory action of hirudin against thrombin-induced death Tested compound Amount administered (µg/10g weight) Score Thrombin + Saline (10 NIH unit/10g weight) 1.7 Thrombin + HV1 (10 NIH unit/10g weight) 100 1.3 200 0.6 500 0.4 Thrombin + HV1C3 (10 NIH unit/10g weight) 20 1.2 50 0.6 100 0.4 As is clear from the table, in the thrombin induced death reaction in vivo , chimeric hirudin (HV1C3) of the present invention exhibited about 4 - 5 times greater inhibitory activity compared with hirudin HV1. [Example 3] Prolongation of bleeding time Samples were injected into male mice (20 - 25g) under anesthesia using sodium pentobarbital (40 mg/kg i.p.) via their tail vein. A puncture wound was made by inserting a 21G needle (outer diameter 0.85 mm) into the other side of the tail vein 5 minutes after the administration of the test compounds, and the bleeding time of the wound was measured. A filter paper was put on the wound, with changes every 15 seconds. Bleeding time is defined as the time required until no red spot is observed on the filter paper. The results are shown in Table 2. Prolongation of bleeding time Tested compound Amount administered (µg/10g weight) Bleeding time (sec) Saline 148.5 ± 14.6 HV1 20 223.7 ± 15.6 50 376.7 ± 20.2 100 501.7 ± 47.1 HV1C3 50 264.0 ± 17.6 100 291.0 ± 30.2 200 369.0 ± 34.9 In general, prolongation of bleeding time is one of the side effects of anti-coagulants. Here, the chimeric hirudin (HV1C3) of the present invention was clearly confirmed to cause less bleeding than hirudin HV1. [Example 4] Preparation having chimeric hirudin HV1C3 as an ingredient The purified chimeric hirudin HV1C3 of the Example 1-(4) was desalted using Sephadex G25 (Pharmacia), followed by filtering through a 0.22 µm filter under sterile conditions. The solution was dispensed into vials and lyophilized. The thus obtained lyophilized powder of chimeric hirudin HV1C3 can be dissolved in saline and used as an injectable drug. Industrial Applicability The present invention provides a new hirudin analog. The hirudin analog of the present invention is useful as an anti-coagulant having strong anti-thrombin activity and a tendency to cause bleeding. Deposits of microorganisms: (1) E . coli JM109/pMTSHV1C3 (Entry E . coli JM109/pMTPHOHV1C3 was amended) Deposit Organization: Fermentation Research Institute, Agency of Industrial Science and Technology, Ministry of International Trade and Industry Address: 1-1-3, Tsukuba-shi Higashi, Ibaraki-ken, Japan Date of Deposit: September 18, 1990 Deposit Number: FERM BP-3104 (2) E . coli RR1/pMTSHV1C3 Deposit Organization: Fermentation Research Institute, Agency of Industrial Science and Technology, Ministry of International Trade and Industry Address: 1-1-3, Tsukuba-shi Higashi, Ibaraki-ken, Japan Date of Deposit: October 11, 1990 Deposit Number: FERM BP-3130 (3) E . coli JM109/pMTSHV1 Deposit Organization: Fermentation Research Institute, Agency of Industrial Science and Technology, Ministry of International Trade and Industry Address: 1-1-3, Tsukuba-shi Higashi, Ibaraki-ken, Japan Date of Deposit: February 6, 1991 Deposit Number: FERM BP-3266 (4) E . coli RR1/pMTSHV3 Deposit Organization: Fermentation Research Institute, Agency of Industrial Science and Technology, Ministry of International Trade and Industry Address: 1-1-3, Tsukuba-shi Higashi, Ibaraki-ken, Japan Date of Deposit: February 6, 1991 Deposit Number: FERM BP-3267

Claims: A hirudin analog, HV1C3, having the amino acid sequence as shown in Formula-1, below: A DNA sequence encoding the amino acid sequence of Formula-1 of claim 1. A transformed microorganism, obtained by transforming E . coli with an expression vector containing a DNA sequence encoding the amino acid sequence of Formula-1 of claim 1 operably linked thereto. A method of manufacturing an hirudin analog, comprising culturing the transformed microorganism described in claim 3, expressing the hirudin analog shown in Formula-1 and recovering it. An anti-coagulation drug having hirudin analog HV1C3 of Formula-1 of claim 1 as an active ingredient.

Inventors: FURUYA HIDEYUKI, INOUE YOSHIFUMI, MATSUDA HITOSHI, MISAWA SATORU, FURUYA, HIDEYUKI, INOUE, YOSHIFUMI, MATSUDA, HITOSHI, MISAWA, SATORU, FURUYA, HIDEYUKI, NIPPON MINING CO., LTD., INOUE, YOSHIFUMI, NIPPON MINING CO., LTD., MATSUDA, HITOSHI, NIPPON MINING CO., LTD., MISAWA, SATORU, NIPPON MINING CO., LTD.
Applicants: JAPAN ENERGY CORP, JAPAN ENERGY CORPORATION
Application year: 1991
Main classification: C07K14
IPC codes: C07K14, C12N9, C12N15, A61K38, C12N1